Featured Research

from universities, journals, and other organizations

FDA Issues Final Rule And Final Order Regarding Safety And Efficacy Of Certain Licensed Biological Products Including Anthrax Vaccine

Date:
December 31, 2003
Source:
U.S. Food And Drug Administration
Summary:
To complete the review of the safety and effectiveness of certain bacterial vaccines and toxoids licensed before July, 1972, FDA today issued a final rule and order that makes final determinations concerning the safety and effectiveness of such products and amends certain biologics regulations.

To complete the review of the safety and effectiveness of certain bacterial vaccines and toxoids licensed before July, 1972, FDA today issued a final rule and order that makes final determinations concerning the safety and effectiveness of such products and amends certain biologics regulations. The final order states FDA's conclusion that the licensed anthrax vaccine, Anthrax Vaccine Adsorbed, is safe and effective for the prevention of anthrax disease - regardless of the route of exposure.

Related Articles


The process of finalizing this rule and order has taken considerable time, as is true with all such documents. Although a District of Columbia Federal Court issued an injunction regarding the anthrax vaccine and its legal status as an approved product recently, FDA made its determinations regarding the anthrax vaccine, as reflected in the final order, long before the court's ruling.

Expert panels were assigned the task of reviewing information on biological products that were licensed under the Public Health Service Act before 1972 when the responsibility for licensing biological products was moved from the National Institutes of Health to the FDA. Based upon their review of the available data, the Expert Panel recommended that the anthrax vaccine, originally licensed in 1970, be classified as a Category I product, meaning that it was safe and effective as it was labeled. The panel recommended that it continue to be licensed on the basis of the evidence of its safety and effectiveness. These findings were originally published in the Federal Register on December 13, 1985.

FDA agreed with the Expert Panel's general recommendation categorizing the vaccine at that time and continues to support that conclusion in this final rule and order.

FDA's final order states that the efficacy analysis in the controlled clinical trial demonstrating the efficacy of the vaccine includes all cases of anthrax disease regardless of the route of exposure or manifestation of disease. Although there were too few inhalation anthrax cases to support an independent statistical analysis, due to the rarity of this method of exposure during the period of time that the study was performed, FDA noted in the final rule that all of the cases of inhalation anthrax that occurred were in unvaccinated individuals. Therefore, the FDA-approved labeling for the anthrax vaccine does not specify the route of exposure, and the vaccine is indicated for active immunization against Bacillus anthracis, independent of the route of exposure. (http://www.fda.gov/cber/products/biopava0131021.htm)

Also, the Institute of Medicine recently conducted an independent review of the licensed anthrax vaccine (http://www.nap.edu/books/0309083095/html/) and concluded that it was a safe and effective vaccine to protect humans against anthrax, including inhalation anthrax.

The Expert Panel that reviewed the licensed anthrax vaccine and other bacterial vaccines and toxoids that had been licensed before 1972 also, as part of its review, classified these products into one of the following categories: Category I - safe, effective and not misbranded; Category II - unsafe, ineffective or misbranded; or Category III - insufficient information, further testing required. The FDA focused its resources initially in addressing those products in category II and III because these posed the greatest potential public health harm. FDA has been working on removing such products from the market and updating the labeling of other products based on the Agency's determinations after the panels' recommendations.

More information about the Panel's report and FDA's conclusions regarding the anthrax vaccine and other products under review can be found soon at http://www.accessdata.fda.gov/scripts/oc/ohrms/advdisplay.cfm.

A recent ruling by a United States District Court for the District of Columbia gave the opinion that the anthrax vaccine should be classified as "investigational" with regard to protecting against inhalation anthrax. Today's final rule and order make it clear that FDA does not regard the approved anthrax vaccine as "investigational" for protection against inhalation anthrax. FDA's final determination of the safety and effectiveness of the anthrax vaccine, independent of route of exposure, as well as its conclusions regarding the Expert Panel's report, being announced today in the final order, are relevant and should be considered in any further litigation in this matter.


Story Source:

The above story is based on materials provided by U.S. Food And Drug Administration. Note: Materials may be edited for content and length.


Cite This Page:

U.S. Food And Drug Administration. "FDA Issues Final Rule And Final Order Regarding Safety And Efficacy Of Certain Licensed Biological Products Including Anthrax Vaccine." ScienceDaily. ScienceDaily, 31 December 2003. <www.sciencedaily.com/releases/2003/12/031231084913.htm>.
U.S. Food And Drug Administration. (2003, December 31). FDA Issues Final Rule And Final Order Regarding Safety And Efficacy Of Certain Licensed Biological Products Including Anthrax Vaccine. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2003/12/031231084913.htm
U.S. Food And Drug Administration. "FDA Issues Final Rule And Final Order Regarding Safety And Efficacy Of Certain Licensed Biological Products Including Anthrax Vaccine." ScienceDaily. www.sciencedaily.com/releases/2003/12/031231084913.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins